Biogen

BIIB

Valor de mercado US$ 34,4 bi

In 12 days, on October 28, Biogen Inc. will publish its results for the third quarter. As a reminder, in late July, the company raised its FY 2026 non-GAAP diluted EPS underlying guidance from $15.25-$16.25 to $15.85-$16.85. In Q2, Biogen's Alzheimer's collaboration revenue rose 16% YoY to $63.7 million.

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development expenses partly offset by higher selling, general and administrative costs.

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

We are only two days into October, and there is already no shortage of volatility. Another surge in Treasury yields and crude prices saw stocks plummet Thursday, but by Friday, a cooldown in both alongside weaker-than-expected nonfarm payrolls data for September is boosting sentiment. As investors begin to look toward this month's upcoming Federal Open Market Committee (FOMC) meeting and more inflation and jobs data, join us in taking a look at 25 stocks you should not bet on during this season of uncertainty.

Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patients with a type of ​autoimmune disease in a mid-stage study.

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest dataset reported for litifilimab in CLE and further support its potential to achieve rapid and durable improvements in skin disease activity. In the study, participants treated with litifilimab in the double-blind, placebo-controlled period showed continued clinical improvements in skin disease activity through Week 52. Notably, participants who switched from placebo to litifilimab treatment at Week 24 experienced a rapid onset of treatment effect as early as four weeks.

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.